The answer to your execution is WHO

Orthopedics companies execute an endless string of projects.  The best Orthopedic companies scale faster because they executing projects better than the competitors.
Leaders in Orthopedics are usually people with backgrounds in Engineering, Sales, Marketing or Finance who are natural-born problem solvers. So when a new initiative is created, the tendency for these leaders is to jump into strategy sessions to create execution plans and timelines. 

No, you are focusing on the HOW. 
This is often the wrong approach. It’s not our fault. We are problem solvers who are all wired for the HOW. We were taught in school to work on the HOW for a new project.  We have been promoted over the years largely because of our HOW planning. 

Focus on the WHO first. 
The right WHO can get you to the finish line faster. 
Identify the WHO first. Once you find the right WHO, he or she will quickly put the plans together and build the right team to execute. He or she may be nearby in another department, or a future employee who is at a competitor, or a consultant who can work full-time for 3 months.
The WHO is often an afterthought, partly because the University system called it cheating if you brought in outside help. We couldn’t phone a friend for an MBA project. But heck, we are in business today. You can use any tools necessary to win the day and scale your business. Find your WHO.

Today is the greatest time in history to find the right WHO for your initiative.  Network. Ask for referrals. Call your favorite recruiter. 
 

Read More

WARNING for Orthos: Get onboard with digital patient health or get run over

New report for medtech industry has stark message: Tech coming for you (MedCityNews)
A new report exhorts the medtech industry to invest in customer-centric capabilities and digital collaborations to build personalized health solutions or die by being outgunned by tech companies with deep expertise and data-driven consumer solutions.
A report released this week at the annual conference of the trade association for medical device and diagnostics companies had a stark message to deliver: invest in customer-centric capabilities and digital collaborations to build personalized health solutions or die.
Die by being outgunned by large tech companies with deep expertise data-driven consumer solutions and unlimited dealmaking capability.
The report — Pulse of the Industry 2018 by Ernst & Young that was published during the MedTech Conference hosted by AdvaMed in Philadelphia that concluded Wednesday — attempts to create the urgency by breaking down an anemic growth rate that has plagued the industry for several years. Even though overall revenue was a record for the industry, revenue growth increased just 4 percent to $379 billion. This was the 10th consecutive year for single-digit revenue growth, and a sharp break from to the 15 percent average annual growth rate achieved from 2000 to 2007.

So, to reverse this trend, the need is to focus on R&D and on longer-term growth strategies instead of short term gains. Here’s how Pamela Spence, EY Global Life Sciences described the state of the industry, in a news release accompanying the report:

Medtechs continue to use conventional strategies, such as buybacks and tuck-in acquisitions, to create scale in must-win therapeutic areas to grow. However, as the shift of power from providers and payers to patients and consumers continues, this business-as-usual approach no longer works. Medtechs must invest in new data and customer-centric capabilities to build stronger ties with consumers or risk being ousted by technology companies and other entrants from outside the sector. To succeed in the digital future, medtechs will be judged not only on the safety and efficacy of their devices and tests, but on their ability to capture and deploy insights from these products to inform care delivery, with a growing emphasis on coordinated care.
In other words data, not devices — the place where the medtech industry lives — represent the digital keys to the coveted kingdom. And it is here that the danger from the tech industry lurks.
Entrants from the tech sector are already eyeing the health space as a fertile area for new growth. In the consumer and search spaces, technology companies have honed their customer engagement and advanced data and analytics skills, including the ability to acquire and securely maintain information, to create more satisfying and personalized customer experiences. They can do the same in health care.
And the challenge from tech is considerable given the heft of their balance sheets and their near unlimited dealmaking ability. The report identified the tech disruptors as Alphabet, Amazon, Apple, CVS Health, Intel, IBM, Microsoft, Samsung, Verizon and Walgreens Boots Alliance, and others.
So what can the industry do today to shore up their defenses and succeed better in the future where consumers and patients are looking for better outcomes and person? The report offered some opportunities for medtech companies to consider investing in:

Collecting and managing growing volumes of patient data in the cloud: patient data remains a largely untapped source of value and one of the biggest near-term opportunities for the industry if they can create secure systems to manage and use it.
Building analytics into care management algorithms using AI.
Recognizing that the clinical insights captured in connected devices will increasingly be the real source of value — rather than the device itself.

But perhaps the loudest message from the E&Y report is one that the medtech industry will find hardest to hear given the reliance on silos and closed systems that guaranteed financial success in the past. The report exhorts the industry to “embed themselves in the health system” and become “serious about customer experience” as well as outcomes which necessarily means partnering and sharing data.
Otherwise risk being replaced.
“Companies continue to focus their efforts on products that are siloed solutions. But the reality is, if you’re offering a siloed solution it’s much easier to be replaced with the next brighter, shinier siloed solution,” said Donald Jones, Scripps Translational Science, in the report.

Read More

A look into the Robot Wars at NASS

NASS 2018: Robotic platforms take center stage (MassDevice)
Medtech companies in the spinal market are rushing to join the robotic revolution, with Medtronic (NYSE:MDT) and Globus Medical (NYSE:GMED) leading the pack, according to a Leerink Partner analyst’s note from the North American Spine Society’s 2018 annual meeting.
In a letter to investors, analyst Richard Newitter suggests that a “growing number of companies,” including Johnson & Johnson (NYSE:JNJ), Zimmer Biomet (NYSE:ZBH) and NuVasive (NSDQ:NUVA), are focused on developing their own spine-focused robotics platforms, and that spinal robotic technologies are “clearly picking up steam and gaining surgeon mindshare.”
Fridley, Minn.-based Medtronic made its move to the front of the pack with its recent $1.6 billion acquisition of Mazor Robotics (NSDQ:MZOR), Newitter wrote. During the company’s analyst session, management commented that “robotics is the most differentiated technology it believes it has seen in spine for over a decade and one that will represent [Medtronic]’s next chapter and point of differentiation going forward to drive share gains,” according to the letter.
Medtronic reportedly said that they felt it was “necessary to own Mazor as some of its integration plans/efforts were just taking too long within the context of separate organizations.” With the acquisition, the medtech giant said it can now accelerate product development initiatives as it looks to maintain its leading position in the category, according to the letter.
The company has plans to release a system which combines Medtronic’s Stealth navigation system with Mazor’s X robotics platform by the end of the year, which Newitter said will be the system Medtronic uses to make a “big incremental push on robotics.”
With the accelerated development and commercialization, Medtronic’s management said they estimate that robotics has the potential to comprise 30% of all spine procedures over the next decade, equating out to approximately $2.4 billion in recurring revenue opportunity, Newitter wrote.
Medtronic’s increased interest in robotics “essentially validates the category,” which will be of big benefit to Globus Medical, Newitter wrote. Medtronic and Mazor’s strategy to place the robotic platforms in exchange for minimum volume commitments opens the door for Globus to do the same, he added, which has the potential to “disproportionately benefit [Globus] given the company’s current low 6-7% US market share position.”
NuVasive put its Pulse integrated navigation platform on display at the conference, Newitter said, and is taking steps to position the platform at the core of its robotic efforts. And while he views the Pulse as a “step in the right direction,” he added that “it still feels like the company is behind on the robotics front.”
Zimmer Biomet showed off a next-gen version of its Rosa robotic platform, which it picked up with its buy of French Medtech SA in 2016. The new platform features upgraded functionality, including integrated navigation and intra-operative planning, but is currently waiting on FDA 510(k) approval, Newitter wrote.
But the system requires k-wires, Newitter said, “which is something that competitive robotic systems don’t require (or are soon moving away from – MDT/Mazor) so this could be an initial disadvantage.” He added that even with approval, he doesn’t think the platform will be a “meaningful player in spine robotics before 2020 at best, and competitive systems could see increased functionality by this time, potentially putting [Zimmer Biomet] at a disadvantage.”
Johnson & Johnson recently inked a deal with Brainlab, and is looking to integrate spinal applications into its Orthotaxy orthopedic robotic platform, which isn’t likely to debut until after 2020, Newitter said.
The company is looking to release an earlier-to-market system as well, which will use Brainlab’s Cirq robotic arm, which is currently pending 510(k) clearance. The system could become available by the end of this year, Newitter wrote, with a next-gen version which could be available as early as next year.

Read More

Dear Engineer in Orthopedics,

For the next month, I am offering FREE CAREER ADVICE for you.

I am a veteran Orthopedics Engineer and a Retained Recruiter – my LinkedIn profile.
I love to share my experience with younger Engineers. I learned a lot in three decades and made a ton of mistakes. I didn’t know anything when I was young. Now I feel like giving back.
I can really help your career with some basic guidance.

Contact

Tiger Buford?Retained Recruiter in Orthopedics
Cell:           (512) 992-9090
Email:         [email protected]
Web:          https://orthostreams.com/
Twitter:       https://twitter.com/TigerBuford
LinkedIn:    https://www.linkedin.com/in/tigerrecruiting/
Instagram:  https://www.instagram.com/tigerbuford

Read More

Top 21 Spine Surgeons under 40 to watch

 
NASS SpineLine’s Inaugural Top 21 Under 40
 

Jared Ament, MD, MPH (Ranchos Palos Verdes, CA)

Brett Braly, MD (Edmond, OK)

David Bumpass, MD (Little Rock, AR)

Berdale Colorado, DO, MPH (St Louis, MO)

Chad Craig, MD FACP (New York, NY)

Areena D’Souza, MBBS, MS (Nottingham, UK)

Sandeep Gidvani, MD (Freemont, CA)

Christina Goldstein, MD FRCSC (Columbia, MO)

Gregory Gullung, MD (Birmingham, AL)

Ram Haddas, PhD, MSc, MEng (Plano, TX)

Clifford Houseman, DO (Southfield, MI)

Samuel Joseph, Jr, MD (Tampa, FL)

John Koerner, MD (Glen Rock, NJ)

Tobias Mattei, MD (St Louis, MO)

Emmaunel Menga, MD (Rochester, NY)

Chukwuka Okafor, MD, MBA (Lakeland, FL)

Kris Radcliff, MD (Egg Harbor Township, NJ)

Bryron Scheider, MD (Nashville, TN)

Andrew Schoenfeld, MD (Boston, MA)

Scott Wagner, MD (Bethesda, MD)

Elizabeth Yu, MD (Columbus, OH)

 

Read More

Technology, Startup News, Career Advice & More

Archives

Pin It on Pinterest

Menu